Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment opt...
Main Authors: | Mehrnoosh Pauls, Stephen Chia, Nathalie LeVasseur |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/29/7/377 |
Similar Items
-
Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
by: Serena Capici, et al.
Published: (2022-07-01) -
Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer
by: Wei Wen, et al.
Published: (2019-08-01) -
Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models
by: Stefania Cocco, et al.
Published: (2022-06-01) -
Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
by: Filomena Marino Carvalho
Published: (2023-11-01) -
Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
by: Patrizia Mancini, et al.
Published: (2014-10-01)